How Peptides Work: Receptor Mechanisms Explained

Peptides are having a moment, but the word gets thrown around without much explanation of what these molecules actually are or how they do anything. The short version: a peptide is a small biological message, and it works by fitting into a receptor the way a key fits a lock — switching that receptor on and letting the cell do the rest. Understand that one mechanism and the entire class, from insulin to the newest triple agonists, stops being a list of brand names and becomes a single coherent idea.

This is a plain-language walkthrough written for research and educational purposes. It describes what the pharmacology literature reports about how peptides signal; it is not medical advice, and the compounds referenced are research compounds not approved for human use.

What is a peptide? (vs a protein, vs a small molecule)

A peptide is a chain of amino acids — usually fewer than about 50 of them — linked end to end. Amino acids are the same twenty building blocks that make up every protein in your body, so a peptide is best thought of as a very short protein fragment with a defined job. ^[8] Where the line sits between "peptide" and "protein" is a matter of length and folding complexity rather than a hard chemical rule: insulin (51 amino acids) sits right at the boundary and is called either, while a molecule like GLP-1 (about 30 amino acids) is squarely a peptide.

That size places peptides in a distinct category from the two other main kinds of drug molecule, and the differences drive almost everything else about how they behave.

The middle column is where peptides live: big enough to be exquisitely selective, small enough to be manufactured by chemical synthesis, but too fragile and too large to survive being swallowed. ^[7] That trade-off — high precision at the cost of oral delivery — is the theme that recurs through the rest of this post.

How do peptides work in the body?

Peptides are the body's messaging system. A gland or tissue releases a peptide hormone into the blood; it travels to a distant tissue; and there it delivers an instruction — release insulin, slow the stomach, burn stored fat. The peptide itself does not carry out the instruction. It only tells the target cell what to do, and the cell's own machinery does the work.

The crucial detail is how the message is delivered. A peptide is a chain of amino acids — large, water-loving, and unable to cross the greasy membrane that surrounds every cell. So unlike many small-molecule drugs, a peptide almost never enters the cell it acts on. Instead it binds a receptor studded in the cell's outer membrane, and that receptor relays the message inward. The peptide stays outside; the signal gets in. This is the single most important idea in peptide pharmacology, so it is worth making the receptor itself concrete.

What is a receptor, and what is a GPCR?

A receptor is a protein that sits in a cell's membrane and waits for a specific signal. One end pokes out of the cell, shaped to grip one particular molecule; the other end reaches into the cell's interior. When the right molecule — its ligand — docks on the outside, the receptor changes shape, and that shape change is transmitted through the membrane to the inside. A signal has crossed a barrier without any molecule crossing with it.

The most important receptor family for peptide drugs is the G-protein-coupled receptor, or GPCR. GPCRs are the largest family of membrane receptors in the human genome, and they are the target of a huge share of all approved medicines. ^[2] Each GPCR winds back and forth across the cell membrane seven times (they are also called "seven-transmembrane" receptors), forming a pocket on the outer surface that a specific ligand slots into. GLP-1, GIP, and glucagon each have their own dedicated GPCR — which is exactly why a single molecule can be engineered to hit one, two, or all three.

Most of the metabolic peptides this site covers act on GPCRs, and they all use a shared internal messenger: binding raises a molecule called cyclic AMP (cAMP) inside the cell, which is what ultimately drives the downstream response. ^[3] The insulin receptor is included to show the contrast — not every peptide receptor is a GPCR, and the ones that are not use a different internal wiring.

Agonist vs antagonist: what is the difference?

Once you know a peptide binds a receptor, the next question is what happens after it binds — and there are two fundamentally different answers.

• An agonist binds the receptor and activates it, producing the receptor's natural downstream effect. It mimics the body's own signal (or improves on it). GLP-1 is a natural agonist of the GLP-1 receptor; semaglutide is a synthetic one.
• An antagonist binds the same receptor but does not activate it. By occupying the pocket, it blocks the natural ligand from getting in — it is a signal blocker rather than a signal sender.

Nearly every peptide in the metabolic and weight-management space is an agonist: the therapeutic goal is to turn up a beneficial signal the body already uses, not to shut one off. Semaglutide, tirzepatide, and retatrutide are all agonists of their target receptors. ^[3] When you read that retatrutide is a "triple agonist," the word is doing precise work — it activates three receptors, rather than blocking them or binding without effect.

There is also useful middle ground: a partial agonist activates a receptor only part-way even when fully bound, which can be a deliberate design choice to balance effect against tolerability. But for the compounds here, full agonism is the operating principle.

How receptor binding becomes a cellular response: signal transduction

Binding is only the trigger. The process that turns "a peptide docked on the surface" into "the cell changed what it is doing" is called signal transduction, and for a GPCR it runs in a recognizable sequence:

1. Binding. The peptide slots into the receptor's outer pocket and the receptor changes shape.
2. G-protein activation. That shape change reaches a G-protein attached to the receptor's inner face and switches it on.
3. Second messenger. The activated G-protein turns on an enzyme that produces a second messenger — for the incretin receptors, that messenger is cyclic AMP (cAMP). ^[3]
4. Amplification. One receptor can activate many G-proteins, and each enzyme makes many messenger molecules, so a handful of bound peptides produces a large internal signal. This amplification is why peptides act at very low (nanomolar) concentrations.
5. Cellular response. The second messenger activates downstream proteins that carry out the actual effect — a pancreatic beta cell releases insulin; a neuron in the appetite circuit fires differently; a liver cell shifts its energy metabolism.

The payoff of understanding this cascade is that it explains the shape of a peptide's effects. Because the peptide never enters the cell, its action depends entirely on how long it stays bound and how much of it is present — which is why pharmacokinetics (covered below) matters so much. And because one receptor drives a specific downstream program, activating it produces a defined, predictable set of effects rather than a scattershot of them.

Why are peptides so selective?

One of the biggest practical advantages of peptides over traditional small-molecule drugs is selectivity — a well-designed peptide tends to hit its intended receptor and very little else. ^[7] The reason is geometric. A small molecule is tiny, so it makes only a few points of contact with its target, and those same few contacts can accidentally fit other proteins too, producing off-target effects. A peptide is a longer chain that folds against its receptor along many points of contact at once — a large, specific interface that no other receptor's pocket matches. More contact points mean a tighter, more discriminating fit.

This is also why peptide side effects tend to be on-target rather than random. When GLP-1 receptor agonists cause nausea and slowed digestion, that is not the drug hitting some unrelated system — it is the same receptor mechanism (slowed gastric emptying is part of how the appetite effect works) showing up as a side effect. Understanding this reframes "side effects" as predictable extensions of the mechanism, not mysterious accidents. It is one of the reasons the metabolic-peptide class has a relatively coherent, well-characterized safety picture despite being potent.

Incretin peptides: GLP-1, GIP, and glucagon (a worked example)

Abstract mechanism becomes concrete with the family of peptides this store is built around: the incretins and their metabolic cousin, glucagon. This is the single best worked example of everything above.

Incretins are gut hormones released when you eat that tell the pancreas to release insulin — but only when blood glucose is actually elevated, a property called glucose-dependent insulin secretion that limits the risk of driving glucose too low. ^[4] The two main incretins are GLP-1 and GIP. A third peptide, glucagon, is not an incretin — it normally raises blood glucose and mobilizes stored energy — but it acts through the same GPCR/cAMP machinery, which is why it can be combined with the incretins in a single molecule.

Here is the elegant part. Each of these three peptides has its own dedicated GPCR, but they belong to the same structural family — their receptors are close relatives. That family resemblance is what makes it chemically possible to design one engineered peptide whose shape fits all three pockets well enough to activate each. You are not bolting three drugs together; you are designing a single amino-acid sequence that is a competent agonist at three related receptors at once. That idea is the entire foundation of the next generation of metabolic compounds.

Retatrutide: triple agonism as the payoff of the mechanism

Everything above leads here. Retatrutide (LY3437943) is a single engineered peptide that acts as an agonist at all three receptors — GLP-1, GIP, and glucagon — simultaneously. ^[5] Semaglutide activates one of the three (GLP-1); tirzepatide activates two (GLP-1 and GIP); retatrutide activates all three. Each added receptor is another GPCR being switched on, another arm of the mechanism contributing.

The reason the field treats this as a new class rather than a stronger version of the old one comes back to what each receptor does. The incretin arms (GLP-1 and GIP) work mainly on the intake side of energy balance — appetite, satiety, insulin. The glucagon arm works on the output side — hepatic energy expenditure and lipid mobilization. Combining them means the molecule is pulling two different levers of metabolism at once, with the incretin arms' glucose control offsetting the glycemic penalty glucagon would carry on its own. ^[5]

And the mechanism cashes out in the trial data. In the Phase 2 obesity trial published in the New England Journal of Medicine, participants on the 12 mg dose lost a mean of 24.2% of body weight at 48 weeks ^[1] — the largest mean reduction reported for a GLP-1-class compound in a controlled trial to date, tracking the stepwise pattern the receptor-coverage thesis predicts: semaglutide (GLP-1) ~15% ^[6], tirzepatide (GLP-1/GIP) ~21%, retatrutide (GLP-1/GIP/glucagon) ~24%. ^[1] For the full receptor-by-receptor breakdown, see how retatrutide works: the triple agonist mechanism; for the complete picture of trial data, dosing, and sourcing, see the complete retatrutide guide.

Peptide pharmacokinetics: half-life and why it matters

If a peptide's effect depends on how much of it is bound to its receptor, then how long the peptide survives in the body is decisive. This is pharmacokinetics — what the body does to the drug over time — and it is where natural peptides and engineered ones diverge sharply.

Natural peptide hormones are meant to be transient signals. Native GLP-1 has a half-life measured in minutes — an enzyme called DPP-4 clips it apart almost as fast as it is released, and the kidneys clear the fragments. ^[4] That is perfect for a real-time "you just ate" signal, but useless for a drug you want to dose once a week. The central achievement of the modern metabolic peptides is pharmacokinetic engineering: reshaping the molecule so it resists DPP-4 and binds to serum albumin (a long-lived blood protein), which stretches the half-life from minutes to days. ^[7] Retatrutide's engineered half-life is roughly 6 days, which is what makes once-weekly dosing possible.

Two practical consequences follow, and both are pure mechanism. First, a long half-life means the drug accumulates toward a steady state over several weeks of repeated dosing — so a peptide's early effects understate what it will do once levels plateau. Second, it means a single missed dose lowers but does not zero out exposure. The full pharmacokinetic story — steady state, clearance, what happens when you stop — is covered in retatrutide's ~6-day half-life.

Why are most peptides injected? (route of administration)

The last piece of the puzzle is the most practical one: why nearly every therapeutic peptide is an injection rather than a pill. The answer is a direct consequence of what a peptide is made of.

A peptide is a chain of amino acids — chemically, it is food. The moment an oral peptide reaches the stomach and small intestine, the same digestive enzymes (proteases) that break down the protein in a meal attack it, chopping it into inactive fragments before it can be absorbed. ^[7] Whatever survives digestion still has to cross the gut wall, and peptides are generally too large and too water-loving to cross efficiently. Between the two barriers, oral bioavailability for most peptides is near zero.

Subcutaneous injection — into the fat layer just under the skin — sidesteps both problems. It deposits the intact peptide where it can be absorbed slowly into the bloodstream, without ever passing through the digestive tract. The slow absorption from a subcutaneous depot also pairs well with a long half-life to produce the smooth, steady exposure that weekly dosing depends on. (A handful of oral peptide products exist, but they require special absorption-enhancing formulations to overcome exactly these barriers, and they still lose most of the dose to digestion.)

This is also why reconstitution and handling matter for research peptides: because the molecule is a fragile protein fragment, rough handling, heat, or repeated freeze-thaw can degrade it before it is ever used. Understanding that the peptide is delicate because of what it is chemically makes careful handling feel less like a rule and more like an obvious consequence of the science.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies; cross-compound comparisons are drawn from separate trials, not head-to-head studies. Retatrutide and the other compounds referenced are research compounds and are not approved for human use.